Granules India Limited (GRANULES.BO)
INR 452.1
(4.85%)
INR 452.1
(4.85%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 8.6 Billion INR | -5.78% |
| 2022 | 9.27 Billion INR | 23.9% |
| 2021 | 7.39 Billion INR | -16.58% |
| 2020 | 8.82 Billion INR | 42.18% |
| 2019 | 5.89 Billion INR | 36.13% |
| 2018 | 4.1 Billion INR | 51.74% |
| 2017 | 2.78 Billion INR | -8.66% |
| 2016 | 3.08 Billion INR | 17.54% |
| 2015 | 2.81 Billion INR | 33.32% |
| 2014 | 2.09 Billion INR | 34.21% |
| 2013 | 1.6 Billion INR | 87.93% |
| 2012 | 822.24 Million INR | 6.94% |
| 2011 | 768.33 Million INR | 34.46% |
| 2010 | 576.56 Million INR | -21.79% |
| 2009 | 737.19 Million INR | 0.0% |
| 2008 | - INR | -100.0% |
| 2007 | 372.88 Million INR | 19.0% |
| 2006 | 313.34 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.59 Billion INR | 1.46% |
| 2023 Q4 | 2.55 Billion INR | 1.82% |
| 2023 Q3 | 2.51 Billion INR | 17.08% |
| 2023 FY | - INR | -5.78% |
| 2023 Q1 | 1.37 Billion INR | -34.98% |
| 2023 Q2 | 2.14 Billion INR | 56.38% |
| 2022 Q4 | 2.1 Billion INR | -9.15% |
| 2022 Q3 | 2.32 Billion INR | -6.24% |
| 2022 FY | - INR | 23.9% |
| 2022 Q1 | 2.16 Billion INR | 16.67% |
| 2022 Q2 | 2.47 Billion INR | 14.58% |
| 2021 Q4 | 1.85 Billion INR | 3.74% |
| 2021 Q1 | 2.09 Billion INR | 5.25% |
| 2021 FY | - INR | -16.58% |
| 2021 Q3 | 1.78 Billion INR | 14.83% |
| 2021 Q2 | 1.55 Billion INR | -25.6% |
| 2020 Q1 | 1.89 Billion INR | 23.38% |
| 2020 Q2 | 2.59 Billion INR | 37.21% |
| 2020 Q4 | 1.98 Billion INR | -12.88% |
| 2020 FY | - INR | 42.18% |
| 2020 Q3 | 2.27 Billion INR | -12.19% |
| 2019 Q4 | 1.53 Billion INR | -7.98% |
| 2019 Q1 | 1.45 Billion INR | 28.95% |
| 2019 Q3 | 1.66 Billion INR | 9.45% |
| 2019 Q2 | 1.52 Billion INR | 4.32% |
| 2019 FY | - INR | 36.13% |
| 2018 Q3 | 1.21 Billion INR | 2.99% |
| 2018 FY | - INR | 51.74% |
| 2018 Q1 | 1.01 Billion INR | 91.31% |
| 2018 Q2 | 1.17 Billion INR | 15.46% |
| 2018 Q4 | 1.13 Billion INR | -6.65% |
| 2017 Q1 | 803.47 Million INR | 2.31% |
| 2017 FY | - INR | -8.66% |
| 2017 Q4 | 533.02 Million INR | -33.16% |
| 2017 Q3 | 797.51 Million INR | -9.99% |
| 2017 Q2 | 886.03 Million INR | 10.27% |
| 2016 FY | - INR | 17.54% |
| 2016 Q4 | 785.36 Million INR | -2.56% |
| 2016 Q3 | 806.03 Million INR | 3.22% |
| 2016 Q2 | 780.87 Million INR | 9.16% |
| 2016 Q1 | 715.35 Million INR | -11.09% |
| 2015 FY | - INR | 33.32% |
| 2015 Q4 | 804.57 Million INR | 20.55% |
| 2015 Q2 | 694.45 Million INR | 8.43% |
| 2015 Q1 | 640.43 Million INR | 35.37% |
| 2015 Q3 | 667.41 Million INR | -3.89% |
| 2014 Q4 | 473.08 Million INR | -14.48% |
| 2014 Q3 | 553.19 Million INR | 4.59% |
| 2014 Q2 | 528.89 Million INR | -0.63% |
| 2014 FY | - INR | 34.21% |
| 2014 Q1 | 532.26 Million INR | 18.89% |
| 2013 Q3 | 455.44 Million INR | 34.27% |
| 2013 Q4 | 447.71 Million INR | -1.7% |
| 2013 Q2 | 339.2 Million INR | 7.45% |
| 2013 Q1 | 315.68 Million INR | 33.24% |
| 2013 FY | - INR | 87.93% |
| 2012 Q3 | 189.96 Million INR | -11.09% |
| 2012 Q4 | 236.92 Million INR | 24.72% |
| 2012 FY | - INR | 6.94% |
| 2012 Q1 | 181.69 Million INR | 0.0% |
| 2012 Q2 | 213.66 Million INR | 17.59% |
| 2011 FY | - INR | 34.46% |
| 2010 FY | - INR | -21.79% |
| 2009 FY | - INR | 0.0% |
| 2008 FY | - INR | -100.0% |
| 2007 FY | - INR | 19.0% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 93.782% |
| NATCO Pharma Limited | 18.79 Billion INR | 54.223% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -83.953% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -1899.605% |
| Achyut Healthcare Limited | 524 Thousand INR | -1641850.382% |
| Ajanta Pharma Limited | 12.56 Billion INR | 31.528% |
| Alkem Laboratories Limited | 24.19 Billion INR | 64.44% |
| Alpa Laboratories Limited | 86.12 Million INR | -9889.69% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 10.533% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -265.064% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 86.075% |
| Bajaj HealthCare Limited | 444.51 Million INR | -1835.548% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -481.72% |
| Brooks Laboratories Limited | 41.72 Million INR | -20518.817% |
| Divi's Laboratories Limited | 25.43 Billion INR | 66.167% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 90.253% |
| Eris Lifesciences Limited | 6.98 Billion INR | -23.15% |
| FDC Limited | 4.4 Billion INR | -95.466% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 24.153% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | -25.367% |
| Gufic Biosciences Limited | 1.48 Billion INR | -481.148% |
| Hester Biosciences Limited | 539.47 Million INR | -1494.865% |
| Indoco Remedies Limited | 2.64 Billion INR | -225.034% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | -25.39% |
| Ipca Laboratories Limited | 13.29 Billion INR | 35.307% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -2559.933% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 10500.256% |
| Lasa Supergenerics Limited | -65.08 Million INR | 13320.375% |
| Laurus Labs Limited | 8 Billion INR | -7.467% |
| Lupin Limited | 36.96 Billion INR | 76.727% |
| Mankind Pharma Limited | 28.09 Billion INR | 69.376% |
| Medicamen Biotech Limited | 245.66 Million INR | -3402.328% |
| Medico Remedies Limited | 150.37 Million INR | -5621.462% |
| Megasoft Limited | 284.73 Million INR | -2921.736% |
| Piramal Pharma Limited | 13.05 Billion INR | 34.098% |
| RPG Life Sciences Limited | 1.28 Billion INR | -571.387% |
| Sigachi Industries Limited | 883.39 Million INR | -873.946% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 330.587% |
| Unichem Laboratories Limited | 742.35 Million INR | -1058.988% |
| Wanbury Limited | 985.49 Million INR | -773.05% |
| Windlas Biotech Limited | 781.72 Million INR | -1000.627% |
| ZIM Laboratories Limited | 462.09 Million INR | -1761.908% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 84.697% |
| Procter & Gamble Health Limited | 3.01 Billion INR | -185.424% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -1160.563% |
| Bal Pharma Limited | 345.59 Million INR | -2389.589% |
| Strides Pharma Science Limited | 3.76 Billion INR | -128.541% |
| Venus Remedies Limited | 711.8 Million INR | -1108.74% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -120.079% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -450.19% |
| Shilpa Medicare Limited | 2.58 Billion INR | -232.453% |
| Aarti Drugs Limited | 3.24 Billion INR | -164.845% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -230.078% |
| Suven Life Sciences Limited | -992.78 Million INR | 966.639% |
| Ind-Swift Limited | 1.06 Billion INR | -707.82% |
| Valiant Laboratories Limited | 12.73 Million INR | -67439.21% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 7.831% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 404.895% |
| Themis Medicare Limited | 562.6 Million INR | -1429.277% |
| Hikal Limited | 2.69 Billion INR | -219.58% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 75.424% |
| Sequent Scientific Limited | 549.8 Million INR | -1464.9% |
| Novartis India Limited | 1.26 Billion INR | -577.84% |
| Wockhardt Limited | 1.08 Billion INR | -696.65% |
| Jubilant Pharmova Limited | 8 Billion INR | -7.467% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -65769.086% |
| Neuland Laboratories Limited | 4.74 Billion INR | -81.202% |
| Morepen Laboratories Limited | 1.72 Billion INR | -398.496% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -2893.414% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -4817.986% |